Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

This phase 3 trial evaluated the efficacy of adding pembrolizumab to standard chemotherapy (paclitaxel carboplatin) in 816 patients with advanced or recurrent endometrial cancer, stratified by mismatch repair (MMR) status. Pembrolizumab significantly improved progression free survival in both MMR deficient (dMMR) and MMR proficient (pMMR) cohorts:

• dMMR cohort: 74% vs. 38% at 12 months (HR 0.30, 95% CI 0.19–0.48).

• pMMR cohort: Median 13.1 vs. 8.7 months (HR 0.54, 95% CI 0.41–0.71).
  Safety profiles were consistent with known pembrolizumab and chemotherapy effects.

This phase 3 trial evaluated the efficacy of adding pembrolizumab to standard chemotherapy (paclitaxel carboplatin) in 816 patients with advanced or recurrent endometrial cancer, stratified by mismatch repair (MMR) status. Pembrolizumab significantly improved progression free survival in both MMR deficient (dMMR) and MMR proficient (pMMR) cohorts:

• dMMR cohort: 74% vs. 38% at 12 months (HR 0.30, 95% CI 0.19–0.48).

• pMMR cohort: Median 13.1 vs. 8.7 months (HR 0.54, 95% CI 0.41–0.71).
  Safety profiles were consistent with known pembrolizumab and chemotherapy effects.